SPRY ARS Pharmaceuticals, Inc.
8-K Current Report
Filed: March 9, 2026
Health Care
Pharmaceutical PreparationsARS Pharmaceuticals, Inc. (SPRY) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results announced March 9, 2026
- • Full detail in Exhibit 99.1 press release — key figures, guidance, and commentary found there
Item 7.01 · Regulation FD Disclosure
- • Updated investor presentation filed March 9, 2026, available on company website and as Exhibit 99.2
- • Reg FD disclosure ensures all investors receive simultaneous access to the same corporate messaging
Get deeper insights on ARS Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.